RU2017120857A - Замещенные аналоги мочевины с мостиковой связью в качестве модуляторов сиртуина - Google Patents
Замещенные аналоги мочевины с мостиковой связью в качестве модуляторов сиртуина Download PDFInfo
- Publication number
- RU2017120857A RU2017120857A RU2017120857A RU2017120857A RU2017120857A RU 2017120857 A RU2017120857 A RU 2017120857A RU 2017120857 A RU2017120857 A RU 2017120857A RU 2017120857 A RU2017120857 A RU 2017120857A RU 2017120857 A RU2017120857 A RU 2017120857A
- Authority
- RU
- Russia
- Prior art keywords
- tetraazatricyclo
- triene
- carboxamide
- phenyl
- trifluoromethyl
- Prior art date
Links
- 102000011990 Sirtuin Human genes 0.000 title 1
- 108050002485 Sirtuin Proteins 0.000 title 1
- 210000002700 urine Anatomy 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 80
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 79
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 37
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 24
- RSOFSSQUFDSBCR-UHFFFAOYSA-N 2-but-2-enylidene-5-butylhex-3-enediamide Chemical compound CC=CC=C(C=CC(CCCC)C(=O)N)C(=O)N RSOFSSQUFDSBCR-UHFFFAOYSA-N 0.000 claims 21
- -1 1-methyl-2-oxo-1,2-dihydropyridin-3-yl Chemical group 0.000 claims 15
- IEWTVWQZVXUUMG-UHFFFAOYSA-N 2-butylnona-3,5,7-trienamide Chemical compound CC=CC=CC=CC(CCCC)C(=O)N IEWTVWQZVXUUMG-UHFFFAOYSA-N 0.000 claims 13
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 13
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 13
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 9
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 claims 4
- 208000002874 Acne Vulgaris Diseases 0.000 claims 3
- 201000004384 Alopecia Diseases 0.000 claims 3
- 206010059313 Anogenital warts Diseases 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 3
- 206010013774 Dry eye Diseases 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 208000001132 Osteoporosis Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 206010040047 Sepsis Diseases 0.000 claims 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 3
- 206010046851 Uveitis Diseases 0.000 claims 3
- 206010052428 Wound Diseases 0.000 claims 3
- 208000027418 Wounds and injury Diseases 0.000 claims 3
- 206010000496 acne Diseases 0.000 claims 3
- 231100000360 alopecia Toxicity 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 201000008937 atopic dermatitis Diseases 0.000 claims 3
- 150000003857 carboxamides Chemical class 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000030533 eye disease Diseases 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 206010023332 keratitis Diseases 0.000 claims 3
- 201000004700 rosacea Diseases 0.000 claims 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 3
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 102000000344 Sirtuin 1 Human genes 0.000 claims 2
- 108010041191 Sirtuin 1 Proteins 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- POLBMHYGYFCEHM-UHFFFAOYSA-N CC=CC=CC=CC(CCCCC)C(=O)N Chemical compound CC=CC=CC=CC(CCCCC)C(=O)N POLBMHYGYFCEHM-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims 1
- 230000035882 stress Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462081916P | 2014-11-19 | 2014-11-19 | |
| US62/081,916 | 2014-11-19 | ||
| PCT/IB2015/058981 WO2016079712A1 (en) | 2014-11-19 | 2015-11-19 | Substituted bridged urea analogs as sirtuin modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2017120857A true RU2017120857A (ru) | 2018-12-19 |
Family
ID=54705247
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017120857A RU2017120857A (ru) | 2014-11-19 | 2015-11-19 | Замещенные аналоги мочевины с мостиковой связью в качестве модуляторов сиртуина |
| RU2017120858A RU2017120858A (ru) | 2014-11-19 | 2015-11-19 | Замещенные аналоги мочевины с мостиковой связью в качестве модуляторов сиртуина |
| RU2017120855A RU2017120855A (ru) | 2014-11-19 | 2015-11-19 | Замещенные аналоги мочевины с мостиковой связью в качестве модуляторов сиртуина |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017120858A RU2017120858A (ru) | 2014-11-19 | 2015-11-19 | Замещенные аналоги мочевины с мостиковой связью в качестве модуляторов сиртуина |
| RU2017120855A RU2017120855A (ru) | 2014-11-19 | 2015-11-19 | Замещенные аналоги мочевины с мостиковой связью в качестве модуляторов сиртуина |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20190048016A1 (OSRAM) |
| EP (4) | EP3220918A1 (OSRAM) |
| JP (4) | JP2017534663A (OSRAM) |
| KR (4) | KR20170083133A (OSRAM) |
| CN (4) | CN107207520A (OSRAM) |
| AU (4) | AU2015348943A1 (OSRAM) |
| BR (4) | BR112017010599A2 (OSRAM) |
| CA (4) | CA2968030A1 (OSRAM) |
| CL (1) | CL2017001275A1 (OSRAM) |
| CO (1) | CO2017004994A2 (OSRAM) |
| CR (1) | CR20170209A (OSRAM) |
| DO (1) | DOP2017000123A (OSRAM) |
| EA (1) | EA201791074A1 (OSRAM) |
| ES (1) | ES2823748T3 (OSRAM) |
| IL (1) | IL252252A0 (OSRAM) |
| MX (1) | MX2017006658A (OSRAM) |
| PE (1) | PE20171257A1 (OSRAM) |
| PH (1) | PH12017500913A1 (OSRAM) |
| RU (3) | RU2017120857A (OSRAM) |
| SG (1) | SG11201703824QA (OSRAM) |
| WO (4) | WO2016079711A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016086088A2 (en) | 2014-11-25 | 2016-06-02 | Northwestern University | Wound healing through sirt1 overexpression |
| CN108329388A (zh) * | 2018-01-18 | 2018-07-27 | 天津市湖滨盘古基因科学发展有限公司 | 一种人的沉默配型信息调节蛋白突变蛋白及其应用 |
| CN108395436B (zh) * | 2018-05-14 | 2021-01-12 | 鹤壁市人民医院 | 一种咪唑并吡嗪医药中间体的制备方法 |
| CN108707150B (zh) * | 2018-05-14 | 2021-04-16 | 江苏惠利生物科技有限公司 | 一种咪唑并吡嗪医药中间体的制备方法 |
| CN110478339A (zh) * | 2019-08-12 | 2019-11-22 | 昆明理工大学 | 紫铆因在制备靶向恢复突变p53构象药物中的应用 |
| KR20220056223A (ko) * | 2019-09-02 | 2022-05-04 | 메르크 파텐트 게엠베하 | 유기 전계발광 디바이스용 재료 |
| US12421204B2 (en) * | 2019-11-19 | 2025-09-23 | Lupin Limited | Process for preparing chroman compounds |
| AU2021207775B2 (en) * | 2020-01-17 | 2025-12-11 | Lupin Limited | Methods, processes and intermediates for preparing chroman compounds |
| CN114890955A (zh) * | 2022-06-23 | 2022-08-12 | 江西瑞威尔生物科技有限公司 | 一种n取代吗啉类有机化合物的制备工艺 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| WO2006094210A2 (en) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Tetrahydroquinoxalinone sirtuin modulators |
| UA108596C2 (xx) | 2007-11-09 | 2015-05-25 | Інгібітори пептиддеформілази | |
| RU2550821C2 (ru) * | 2009-10-29 | 2015-05-20 | Сертрис Фармасьютикалз, Инк. | Бициклические пиридины и аналоги в качестве модуляторов сиртуина |
| AU2012352442A1 (en) * | 2011-12-12 | 2014-07-03 | Smb Innovation Aps | Novel heterocyclic compounds useful in sirtuin binding and modulation |
| BR112015028613A2 (pt) * | 2013-05-13 | 2017-07-25 | Glaxosmithkline Llc | análogos de uréia com ligações por pontes substituída como moduladores de sirtuína |
-
2015
- 2015-11-19 ES ES15801271T patent/ES2823748T3/es active Active
- 2015-11-19 WO PCT/IB2015/058980 patent/WO2016079711A1/en not_active Ceased
- 2015-11-19 AU AU2015348943A patent/AU2015348943A1/en not_active Abandoned
- 2015-11-19 JP JP2017526875A patent/JP2017534663A/ja not_active Withdrawn
- 2015-11-19 PE PE2017000883A patent/PE20171257A1/es not_active Application Discontinuation
- 2015-11-19 KR KR1020177016277A patent/KR20170083133A/ko not_active Withdrawn
- 2015-11-19 AU AU2015348942A patent/AU2015348942B2/en not_active Ceased
- 2015-11-19 BR BR112017010599A patent/BR112017010599A2/pt not_active Application Discontinuation
- 2015-11-19 MX MX2017006658A patent/MX2017006658A/es unknown
- 2015-11-19 JP JP2017526950A patent/JP2017534664A/ja active Pending
- 2015-11-19 BR BR112017010595-0A patent/BR112017010595A2/pt not_active Application Discontinuation
- 2015-11-19 US US15/527,851 patent/US20190048016A1/en not_active Abandoned
- 2015-11-19 CN CN201580073769.9A patent/CN107207520A/zh active Pending
- 2015-11-19 JP JP2017526852A patent/JP6806679B2/ja not_active Expired - Fee Related
- 2015-11-19 BR BR112017010602A patent/BR112017010602A2/pt not_active Application Discontinuation
- 2015-11-19 KR KR1020177016279A patent/KR20170087907A/ko not_active Withdrawn
- 2015-11-19 CA CA2968030A patent/CA2968030A1/en not_active Abandoned
- 2015-11-19 WO PCT/IB2015/058977 patent/WO2016079709A1/en not_active Ceased
- 2015-11-19 EP EP15804601.1A patent/EP3220918A1/en not_active Withdrawn
- 2015-11-19 WO PCT/IB2015/058978 patent/WO2016079710A1/en not_active Ceased
- 2015-11-19 KR KR1020177016278A patent/KR20170083134A/ko not_active Withdrawn
- 2015-11-19 EA EA201791074A patent/EA201791074A1/ru unknown
- 2015-11-19 SG SG11201703824QA patent/SG11201703824QA/en unknown
- 2015-11-19 KR KR1020177016280A patent/KR20170083135A/ko not_active Withdrawn
- 2015-11-19 CA CA2968032A patent/CA2968032A1/en not_active Abandoned
- 2015-11-19 CR CR20170209A patent/CR20170209A/es unknown
- 2015-11-19 RU RU2017120857A patent/RU2017120857A/ru unknown
- 2015-11-19 JP JP2017526965A patent/JP2017534665A/ja active Pending
- 2015-11-19 BR BR112017010601A patent/BR112017010601A2/pt not_active Application Discontinuation
- 2015-11-19 RU RU2017120858A patent/RU2017120858A/ru unknown
- 2015-11-19 EP EP15816522.5A patent/EP3221322A1/en not_active Withdrawn
- 2015-11-19 US US15/527,440 patent/US20170355705A1/en not_active Abandoned
- 2015-11-19 US US15/527,581 patent/US10072011B2/en not_active Expired - Fee Related
- 2015-11-19 AU AU2015348941A patent/AU2015348941A1/en not_active Abandoned
- 2015-11-19 CN CN201580073897.3A patent/CN107207509B/zh not_active Expired - Fee Related
- 2015-11-19 EP EP15801271.6A patent/EP3221317B1/en active Active
- 2015-11-19 CN CN201580073311.3A patent/CN107108627A/zh active Pending
- 2015-11-19 CA CA2968027A patent/CA2968027A1/en not_active Abandoned
- 2015-11-19 EP EP15801270.8A patent/EP3221316A1/en not_active Withdrawn
- 2015-11-19 AU AU2015348944A patent/AU2015348944A1/en not_active Abandoned
- 2015-11-19 RU RU2017120855A patent/RU2017120855A/ru unknown
- 2015-11-19 CA CA2968029A patent/CA2968029A1/en not_active Abandoned
- 2015-11-19 CN CN201580073782.4A patent/CN107207521A/zh active Pending
- 2015-11-19 WO PCT/IB2015/058981 patent/WO2016079712A1/en not_active Ceased
- 2015-11-19 US US15/527,941 patent/US20180319810A1/en not_active Abandoned
-
2017
- 2017-05-11 IL IL252252A patent/IL252252A0/en unknown
- 2017-05-17 PH PH12017500913A patent/PH12017500913A1/en unknown
- 2017-05-18 DO DO2017000123A patent/DOP2017000123A/es unknown
- 2017-05-18 CL CL2017001275A patent/CL2017001275A1/es unknown
- 2017-05-19 CO CONC2017/0004994A patent/CO2017004994A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017120857A (ru) | Замещенные аналоги мочевины с мостиковой связью в качестве модуляторов сиртуина | |
| BR112012017713A2 (pt) | Aminopiridina, formulação farmacêutica, processo para a preparação de um derivado de aminopiridina, intermediário, e, uso de uma aminopiridina ou de uma formulação farmacêutica | |
| RU2017120217A (ru) | 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1 | |
| RU2016127623A (ru) | Производные бензотриазола в качестве модуляторов активности tnf | |
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| RU2017121044A (ru) | Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы | |
| RU2017116197A (ru) | 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 для лечения болезни альцгеймера | |
| JP2020502111A5 (OSRAM) | ||
| RU2016132858A (ru) | Производные фторнафтила | |
| HRP20220314T1 (hr) | Spojevi n-((het)arilmetil)-heteroaril-karboksamida kao plazma kallikrein inhibitori | |
| RU2016133626A (ru) | 2-амино-3,5,5-трифтор-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 для лечения болезни альцгеймера | |
| FI3555076T3 (fi) | Uusia fenyylipropionihappojohdannaisia ja niiden käyttötapoja | |
| JP2017530999A5 (OSRAM) | ||
| JP2016523977A5 (OSRAM) | ||
| HRP20160678T1 (hr) | Derivati 2-(1,2,3-triazol-2-il)benzamida i 3-(1,2,3-triazol-2-il)pikolinamida kao antagonisti receptora oreksina | |
| ME03723B (me) | 2-amin0-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridini kао васе1 inhibiтori | |
| AR082458A1 (es) | Combinacion que comprende un farmaco antipsicotico y un agonista de taar1 | |
| RU2015100942A (ru) | Производное пиперидинилпиразолпиридина | |
| PE20220711A1 (es) | Derivados de 2-isoindol-1,3,4-oxadiazol utiles como inhibidores de la histona desacetilasa 6 (hdac6) | |
| RU2018138047A (ru) | Гетероциклические вещества - агонисты gpr119 | |
| JP2016534124A5 (OSRAM) | ||
| JP2016523976A5 (OSRAM) | ||
| RU2017120859A (ru) | Замещенные мостиковые аналоги мочевины в качестве модуляторов сиртуина | |
| JP2020503293A5 (OSRAM) | ||
| BR112015004613A2 (pt) | agonistas para o receptor trpm-8; combinações de substâncias ativas de agonistas; preparações cosméticas ou dermatológicas contendo um ou mais agonistas de trpm-8, um ou mais polióis, e uma ou mais substâncias de ação antieritematosa ou inibidora de inflamação |